Valuation: Incyte Corporation

Market Cap 23.32B 20.4B 18.81B 17.37B 32.97B 2,224B 33.52B 225B 88.27B 1,096B 87.55B 85.64B 3,766B P/E 2026 *
37.9x
P/E 2027 * 17.3x
Enterprise Value 18.3B 16.01B 14.76B 13.63B 25.87B 1,745B 26.31B 176B 69.27B 860B 68.7B 67.21B 2,955B EV / Sales 2026 *
3.25x
EV / Sales 2027 * 2.68x
Free-Float
98.1%
Yield 2026 *
-
Yield 2027 * -
1 day-1.53%
1 week-0.13%
Current month+2.96%
1 month+10.74%
3 months+21.48%
6 months+9.21%
Current year+18.16%
1 week 114.27
Extreme 114.27
118.97
1 month 96.09
Extreme 96.09
118.97
Current year 89.25
Extreme 89.25
118.97
1 year 67.17
Extreme 67.17
118.97
3 years 50.27
Extreme 50.27
118.97
5 years 50.27
Extreme 50.27
118.97
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 2025-06-25
Director of Finance/CFO 57 2026-05-03
President 62 2023-06-04
Director TitleAgeSince
Chairman 59 2025-06-25
Director/Board Member 72 2015-01-19
Director/Board Member 64 2015-01-19
Date Insider Type Main position Quantity % Market Cap.
07-01Tax

EVP & Chief Scientific Officer

-350 0.0002%
07-01Tax

Chief Executive Officer

-4,779 0.0024%
07-01Tax

Chief Technology Officer

-2,177 0.0011%
Change 5-day change 1-year change 3-year change Capi.($)
-1.53%-0.13%+65.92%+88.58% 23.32B
-0.51%+1.57%+18.72%-5.52% 67.61B
-5.16%-8.63%+37.37%+202.27% 51.6B
+5.28%+39.50%+39.50%+39.50% 43B
-2.10%+0.89%-49.30%-53.47% 40.94B
+0.12%-7.85%+47.16%-29.27% 29.4B
-10.83%-14.41%+99.15%-44.54% 27.09B
+3.88%+2.16%+11.78%+201.51% 19.89B
-1.59%-1.63%+61.04%+130.75% 16.91B
-4.75%+11.27%+85.63%+394.76% 16.84B
Average -1.72%-1.59%+41.70%+92.46% 33.66B
Weighted average by Cap. -1.53%-2.13%+33.25%+66.66%

Financials

2026 *2027 *
Net sales 5.63B 4.92B 4.54B 4.19B 7.96B 537B 8.09B 54.24B 21.3B 264B 21.13B 20.67B 909B 6.14B 5.37B 4.95B 4.57B 8.67B 585B 8.82B 59.14B 23.23B 288B 23.04B 22.53B 991B
Net income 637M 557M 514M 475M 900M 60.74B 916M 6.14B 2.41B 29.92B 2.39B 2.34B 103B 1.4B 1.23B 1.13B 1.05B 1.99B 134B 2.02B 13.54B 5.32B 65.98B 5.27B 5.16B 227B
Net Debt -5.02B -4.39B -4.05B -3.74B -7.1B -479B -7.22B -48.38B -19B -236B -18.84B -18.43B -811B -6.87B -6.01B -5.55B -5.12B -9.72B -656B -9.88B -66.26B -26.02B -323B -25.81B -25.25B -1,110B
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
26-07-10 US$116.71 -1.53% 1,643,980
26-07-09 US$118.52 +1.07% 1,353,569
26-07-08 US$117.26 -0.67% 1,878,406
26-07-07 US$118.05 +2.10% 1,667,760
26-07-06 US$115.62 -1.06% 1,277,144
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
116.71USD
Average target price
111.45USD
Spread / Average Target
-4.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock